API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
0
Other Certificates
Other Suppliers
USA (Orange Book)
Europe
Canada
Australia
0
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
Details:
GIMOTI (metoclopramide) nasal spray, for relief of symptoms associated with acute and recurrent diabetic gastroparesis in adults, has been added to Texas Medicaid PDL, supports reimbursement for GIMOTI on Texas Medicaid formulary and associated program.
Lead Product(s): Metoclopramide Hydrochloride
Therapeutic Area: Gastroenterology Product Name: Gimoti
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable April 19, 2022
Details:
Gimoti is Evoke’s nasal spray product for the relief of symptoms in acute and recurrent diabetic gastroparesis. The patent covers methods of use for nasal delivery of metoclopramide for the treatment of gastroparesis.
Lead Product(s): Metoclopramide Hydrochloride
Therapeutic Area: Gastroenterology Product Name: Gimoti
Highest Development Status: ApprovedProduct Type: Small molecule
Partner/Sponsor/Collaborator: Not Applicable
Deal Size: Not Applicable Upfront Cash: Not Applicable
Deal Type: Not Applicable June 02, 2021